Overview

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the EGFR inhibitor, Cetuximab in patients with mCRC harboring APC, TP53 and KRAS/NRAS mutations.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Treatments:

Cetuximab